FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2217551402> ?p ?o ?g. }

• W2217551402 endingPage "520" @default.
• W2217551402 startingPage "512" @default.
• W2217551402 abstract "BACKGROUND Prognostic factors associated with clinical outcomes in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with a novel androgen receptor‐directed therapies (ARDT) in the second line setting has not been formally evaluated. PATIENTS AND METHODS We retrospectively reviewed and analyzed medical records of all patients with mCRPC who received sequential treatment with ARDT. We analyzed potential clinical factors associated with post treatment endpoints including 50% decline in prostatic‐specific antigen (PSA), PSA‐progression‐free survival (PFS), clinical or radiographic PFS and overall survival (OS). Prognostic univariate and multivariate Cox proportional hazard models were developed and assessed. RESULTS One hundred twenty‐six patients with mCRPC treated with a second‐line novel ARDT were included. Overall, 50% decline in PSA was observed in 22% of patients and a median PSA‐PFS of 2.9 months and a PFS of 3.6 months. After adjusting for potential confounders including prior exposure to docetaxel and number of prior antiandrogen agents, time to development of CRPC was an independent factor associated with PSA‐PFS (hazard ratio [HR]: 0.99; 95% confidence interval [CI]: 0.99–1; P = 0.02) and PFS (HR: 0.99; CI: 0.98–1; P = 0.01). PSA response (50% decline) to first‐line novel ARDT correlated negatively with PSA‐PFS with second‐line novel ARDT (HR: 1.7; 95% CI: 1.14–2.53; P = 0.009) and lower pre‐treatment levels of albumin were associated with shorter PFS (HR: 0.56; 95% CI: 0.32‐0.97; P = 0.03). Performance status, pre‐treatment levels of albumin, extent of disease and time to development CRPC were associated with OS. CONCLUSIONS Second‐line ARDT is associated with modest outcomes in patients with mCRPC. Time to development of CRPC is the strongest predictor of PSA response, PSA‐PFS and OS which suggest that intrinsic resistance to AR directed treatment is the major treatment outcome factor in these patients. Future studies in patients receiving long term ARTD should include the identification of predictive biomarkers to facilitate treatment selection. Prostate 76:512–520, 2016 . © 2015 Wiley Periodicals, Inc." @default.
• W2217551402 created "2016-06-24" @default.
• W2217551402 creator A5001783218 @default.
• W2217551402 creator A5009105768 @default.
• W2217551402 creator A5012074439 @default.
• W2217551402 creator A5018645768 @default.
• W2217551402 creator A5020274632 @default.
• W2217551402 creator A5036285787 @default.
• W2217551402 creator A5055397277 @default.
• W2217551402 creator A5088048189 @default.
• W2217551402 date "2015-12-22" @default.
• W2217551402 modified "2023-10-14" @default.
• W2217551402 title "Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies" @default.
• W2217551402 cites W1755643198 @default.
• W2217551402 cites W1844925317 @default.
• W2217551402 cites W1980244461 @default.
• W2217551402 cites W2019607817 @default.
• W2217551402 cites W2077244514 @default.
• W2217551402 cites W2080439368 @default.
• W2217551402 cites W2110534364 @default.
• W2217551402 cites W2118564089 @default.
• W2217551402 cites W2120292596 @default.
• W2217551402 cites W2121023961 @default.
• W2217551402 cites W2131109308 @default.
• W2217551402 cites W2137467802 @default.
• W2217551402 cites W2139995572 @default.
• W2217551402 cites W2148643283 @default.
• W2217551402 cites W2150865892 @default.
• W2217551402 cites W2154368013 @default.
• W2217551402 cites W2156923287 @default.
• W2217551402 cites W2166918329 @default.
• W2217551402 cites W2167331614 @default.
• W2217551402 doi "https://doi.org/10.1002/pros.23141" @default.
• W2217551402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26689606" @default.
• W2217551402 hasPublicationYear "2015" @default.
• W2217551402 type Work @default.
• W2217551402 sameAs 2217551402 @default.
• W2217551402 citedByCount "17" @default.
• W2217551402 countsByYear W22175514022016 @default.
• W2217551402 countsByYear W22175514022017 @default.
• W2217551402 countsByYear W22175514022018 @default.
• W2217551402 countsByYear W22175514022019 @default.
• W2217551402 countsByYear W22175514022020 @default.
• W2217551402 countsByYear W22175514022021 @default.
• W2217551402 crossrefType "journal-article" @default.
• W2217551402 hasAuthorship W2217551402A5001783218 @default.
• W2217551402 hasAuthorship W2217551402A5009105768 @default.
• W2217551402 hasAuthorship W2217551402A5012074439 @default.
• W2217551402 hasAuthorship W2217551402A5018645768 @default.
• W2217551402 hasAuthorship W2217551402A5020274632 @default.
• W2217551402 hasAuthorship W2217551402A5036285787 @default.
• W2217551402 hasAuthorship W2217551402A5055397277 @default.
• W2217551402 hasAuthorship W2217551402A5088048189 @default.
• W2217551402 hasBestOaLocation W22175514022 @default.
• W2217551402 hasConcept C121608353 @default.
• W2217551402 hasConcept C126322002 @default.
• W2217551402 hasConcept C126894567 @default.
• W2217551402 hasConcept C143998085 @default.
• W2217551402 hasConcept C144301174 @default.
• W2217551402 hasConcept C207103383 @default.
• W2217551402 hasConcept C2776551883 @default.
• W2217551402 hasConcept C2776694085 @default.
• W2217551402 hasConcept C2780192828 @default.
• W2217551402 hasConcept C2780739268 @default.
• W2217551402 hasConcept C2781190966 @default.
• W2217551402 hasConcept C2781406297 @default.
• W2217551402 hasConcept C38180746 @default.
• W2217551402 hasConcept C44249647 @default.
• W2217551402 hasConcept C50382708 @default.
• W2217551402 hasConcept C61367390 @default.
• W2217551402 hasConcept C71924100 @default.
• W2217551402 hasConceptScore W2217551402C121608353 @default.
• W2217551402 hasConceptScore W2217551402C126322002 @default.
• W2217551402 hasConceptScore W2217551402C126894567 @default.
• W2217551402 hasConceptScore W2217551402C143998085 @default.
• W2217551402 hasConceptScore W2217551402C144301174 @default.
• W2217551402 hasConceptScore W2217551402C207103383 @default.
• W2217551402 hasConceptScore W2217551402C2776551883 @default.
• W2217551402 hasConceptScore W2217551402C2776694085 @default.
• W2217551402 hasConceptScore W2217551402C2780192828 @default.
• W2217551402 hasConceptScore W2217551402C2780739268 @default.
• W2217551402 hasConceptScore W2217551402C2781190966 @default.
• W2217551402 hasConceptScore W2217551402C2781406297 @default.
• W2217551402 hasConceptScore W2217551402C38180746 @default.
• W2217551402 hasConceptScore W2217551402C44249647 @default.
• W2217551402 hasConceptScore W2217551402C50382708 @default.
• W2217551402 hasConceptScore W2217551402C61367390 @default.
• W2217551402 hasConceptScore W2217551402C71924100 @default.
• W2217551402 hasFunder F4320307758 @default.
• W2217551402 hasIssue "5" @default.
• W2217551402 hasLocation W22175514021 @default.
• W2217551402 hasLocation W22175514022 @default.
• W2217551402 hasLocation W22175514023 @default.
• W2217551402 hasOpenAccess W2217551402 @default.
• W2217551402 hasPrimaryLocation W22175514021 @default.
• W2217551402 hasRelatedWork W122177069 @default.
• W2217551402 hasRelatedWork W2135620818 @default.
• W2217551402 hasRelatedWork W2274307715 @default.

• next